Latest Breaking News On - Biocity biopharma - Page 2 : comparemela.com

Contrasting GSK (NYSE:GSK) & AstraZeneca (OTCMKTS:AZNCF)

Contrasting GSK (NYSE:GSK) & AstraZeneca (OTCMKTS:AZNCF)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesBricanyl respulesFarxiga forxigaDuaklir genuairDaliresp daxasBiocity biopharmaBrilinta briliqueBydureon byettaAndexxa ondexxyaCholesgen shanghai co ltdPersonalis incZeneca groupSernova corpGet free reportGiven astrazeneca

Riding the tide, realize the future: The BD paths for Chinese Biotech

Riding the tide, realize the future: The BD paths for Chinese Biotech
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Yong jiangBiocity biopharmaceuticsIvy wangBristol myer squibbKaan certelBiocity biopharmaXiang bo jiaJapan national institute of scienceKoch institute for integrative cancer researchUniversity of iowaTechnology policyGlobal headOncology external innovationChief business officerBiocity pharmaceuticsJiang hei

BioCity announces FDA clearance of Investigational New Drug application for its first-in-class CD3/EGFR bispecific antibody

/PRNewswire/ BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company s Investigational New Drug (IND).

United statesBiocity biopharmaPrnewswire biocity biopharmaDrug administrationCity biopharmaInvestigational new drug

BioCity announces the first patient dosed with its first-in-class CDH3-targeting ADC BC3195 in a Phase 1 Trial

BioCity announces the first patient dosed with its first-in-class CDH3-targeting ADC BC3195 in a Phase 1 Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Prnewswire biocity biopharmaBiocity biopharmaCity biopharma

BioCity Announces Initiation of a Phase 2 Trial for SC0062, a Promising ETA Receptor Antagonist for Chronic Kidney Disease

/PRNewswire/ BioCity Biopharma, a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent.

Yong jiangPrnewswire biocity biopharmaBiocity biopharmaCity biopharmaYong jiang hei